Celebrating Success: METRC's Award-Winning Contributions Shine at OTA 2026
METRC had another strong showing at the 2026 Orthopaedic Trauma Association (OTA) Annual Meeting in Nashville, with 10 podium presentations showcasing findings from across the consortium’s research portfolio. More broadly, the meeting provided an opportunity to reflect on another successful year for METRC and on the remarkable scale of what the consortium has built through collaboration among investigators, research teams, patients, and partners across the country.
One of the clearest measures of that success is METRC’s ability to implement large, multicenter studies across a broad and highly engaged network. Ninety sites have now enrolled at least one patient in a METRC study, with more than 25,000 participants enrolled across the consortium. The current METRC portfolio includes 38 studies, with 22 completed with analysis finished, eight completed with analyses underway, and eight ongoing. Those numbers capture the consortium’s major prospective studies, but they do not fully reflect the foundational work that has made them possible, including retrospective studies, pilot and feasibility projects, and other collaborative efforts used to refine research questions and prepare for large prospective randomized trials. Taken together, this body of work demonstrates not only METRC’s reach, but its ability to move important clinical questions from early investigation through rigorous multicenter evaluation.
Disseminating the results of that work is equally important. This year’s 10 METRC podium presentations at OTA shared findings from across the portfolio with one of the most important professional audiences in orthopaedic trauma. Each year, METRC research represents a meaningful presence within the OTA scientific program, creating an opportunity not only to disseminate results through peer-reviewed publications, but also to engage directly with surgeons, investigators, and other members of the orthopaedic trauma community. That multipronged approach allows findings to reach the people who can put them into practice while also generating discussion, new ideas, and enthusiasm for future collaborative research.
METRC also continued to develop and submit new proposals throughout 2026, despite an increasingly challenging and competitive funding environment. Sustaining the consortium depends not only on securing funding for new research, but also on developing the next generation of investigators who will lead it. Many of METRC’s current senior investigators were themselves early-career investigators when the consortium began. Today, they are mentoring a new generation of surgeon-scientists, and an increasing number of new concepts and grant proposals are being developed in partnership with young investigators as they refine their ideas and build experience leading large-scale multicenter research.
The METRC Annual Meeting also provided an opportunity to recognize the many individuals and sites whose work makes these accomplishments possible. Annual awards celebrated excellence in enrollment, follow-up, site performance, investigation, publication, study implementation, and data quality, a reflection of the many different contributions required to successfully conduct high-quality multicenter research.
None of this work would be possible without the patients and families who choose to participate in METRC studies, as well as the patients, caregivers, and other community partners who help shape the research itself. Their contributions extend well beyond study participation. By partnering with METRC investigators during study development, they help identify the questions that matter most to patients and ensure that the outcomes being measured reflect what is meaningful in recovery after orthopaedic trauma.
OTA 2026 offered a chance to celebrate how far the consortium has come while also looking ahead to what comes next. METRC’s continued success rests on the same foundation that has sustained it from the beginning: a broad collaborative network committed to answering important clinical questions that no single institution could address alone, and to translating those answers into better evidence for patients and clinicians.